



LABORATORY REPORT

Example Client, XYZ123
1234 Warde Road
Ann Arbor MI 48108

EXAMPLE, REPORT W
WX0000003826 F 12/05/1988 34 Y

Referral Testing

Collected: 09/19/2023 10:37 Received: 09/19/2023 10:37

Table with 6 columns: Test Name, Result, Flag, Ref-Ranges, Units, Site. Row 1: Marijuana Metabolite, Umbilical Cord Tissue, Qualitative, Present, Cutoff 0.2, ng/g, ARRL

INTERPRETIVE INFORMATION: Marijuana Metabolite, Umbilical Cord Tissue, Qualitative
Methodology: Qualitative Liquid Chromatography-Tandem Mass Spectrometry

This test is designed to detect and document exposure that occurred during approximately the last trimester of a full term pregnancy, to a common cannabis (marijuana) metabolite. Alternative testing is available to detect other drug exposures. The pattern and frequency of drug(s) used by the mother cannot be determined by this test. A negative result does not exclude the possibility that a mother used drugs during pregnancy. Detection of drugs in umbilical cord tissue depends on extent of maternal drug use, as well as drug stability, unique characteristics of drug deposition in umbilical cord tissue, and the performance of the analytical method. Drugs administered during labor and delivery may be detected. Detection of drugs in umbilical cord tissue does not insinuate impairment and may not affect outcomes for the infant. Interpretive questions should be directed to the laboratory.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.
Performed By: ARUP Laboratories
500 Chipeta Way
Salt Lake City, UT 84108
Laboratory Director: Jonathan R. Genzen, MD, PhD
CLIA Number: 46D0523979

Performing Site:

ARRL: ARUP REFERENCE LAB 500 Chipeta Way Salt Lake City UT 841081221

Reported Date: 2023.09.19 10:37

LAB: L - LOW, H - HIGH, AB - ABNORMAL, C - CRITICAL, . - NOT TESTED